A drug that could help people who suffer from a genetic disorder that causes them to feel pain when exposed to sunlight has performed well in its Phase III crossover trial.
Scenesse was evaluated for its ability to provide preventative pharmaceutical therapy for patients with erythropoietic protoporphyria (EPP), which causes phototoxic reactions following exposure to sunlight.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The 12-month, 91-patient trial showed that patients receiving Scenesse experienced significantly lowered pain severity compared to those receiving a placebo.
The duration of exposure to sunlight and melanin levels were found to be higher following active drug treatment.
Clinuvel Pharmaceuticals, who carried out the trial, said the results demonstrate Scenesse as a systemic photoprotectant in EPP patients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
